OncoBreak: 'Bad at Death'; Environment and Ca; Dr. vs Dad

"We're bad at death." An ICU physician talks about end-of-life decisions and discussions with terminally ill patients and their families. (New York Times)

The FDA approved the PD-1 inhibitor pembrolizumab (Keytruda) for use with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, irrespective of the tumor's PD-L1 status. (Merck)

Cells targeted by immunotherapy in advanced non-small cell lung cancer appear early in the course of the disease, suggesting an expanded role for the therapies. (Mount Sinai Hospital, Cell)

More evidence that environmental factors are at the root of many cancers. (Cancer)

Women with metastatic breast cancer worry about their status vis-à-vis pre-existing illness under new healthcare legislation. (ABC News)

MD Anderson Cancer Center and the American Dental Association joined forces in an effort to increase awareness about immunization against human papillomavirus and smoking cessation to prevent cancer.

The American College of Radiology was called on the carpet for "fear mongering" because of a press release promoting a study about the natural history of untreated screen-detected breast cancer. (Health News Reviews)

An enhanced recovery strategy that led to shorter hospital stays after colorectal surgery resulted in similar outcomes in other types of abdominal and pelvic surgery. (Roswell Park Cancer Institute)

A retrospective tissue-based study suggested that selecting treatment for pancreatic cancer on the basis of tumor genetics has potential to improve outcomes. (University of Pittsburgh Medical Center)

Doctor versus Dad -- It's a no-brainer for this oncologist. (ASCO Connection)

Darker skin does not mean a lower risk, and other myths about skin cancer. (American Cancer Society)

Comment